P/E ratio for Edwards Lifesciences (EW)
P/E ratio as of July 2025 (TTM): 11.2
According to Edwards Lifesciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.1969. At the end of 2024 the company had a P/E ratio of 10.6.
P/E ratio history for Edwards Lifesciences from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 10.6 | -67.87% |
| 2023 | 33.0 | 8.39% |
| 2022 | 30.5 | -43.11% |
| 2021 | 53.5 | -22.74% |
| 2020 | 69.3 | 49.1% |
| 2019 | 46.5 | 4.37% |
| 2018 | 44.5 | 16.54% |
| 2017 | 38.2 | 8.87% |
| 2016 | 35.1 | 1.98% |
| 2015 | 34.4 | 106.95% |
| 2014 | 16.6 | -11.75% |
| 2013 | 18.8 | -46.71% |
| 2012 | 35.4 | 3.53% |
| 2011 | 34.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 76.7 | 584.97% | 🇺🇸 USA |
 Merit Medical MMSI | 40.4 | 260.92% | 🇺🇸 USA |
 LeMaitre Vascular LMAT | 40.8 | 264.63% | 🇺🇸 USA |
 CryoLife CRY | N/A | N/A | 🇺🇸 USA |
 Medtronic MDT | 27.9 | 148.91% | 🇮🇪 Ireland |
 ICU Medical
ICUI | -33.3 | -397.31% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.